Skip to Content

Posts tagged with "Drug Industry History"

  • Business and Markets

    Did Pfizer Cut Back Some of Its Best Compounds?

    John LaMattina has a look at Pfizer’s oncology portfolio, and what their relentless budget-cutting has been doing to it. The company is taking some criticism for having outlicensed two compounds (tremelimumab to AstraZeneca and neratinib to Puma) which seem to be performing very well after Pfizer ditched them. Here’s LaMattina (a former… Read More
  • Drug Industry History

    Abandoned Pharma

    It’s not the most cheerful topic in the world, but NPR recently had an item on the decommissioned pharma research sites of New Jersey (of which there are many). Some of these are quite large, and correspondingly hard to unload onto anyone else. (This is, of course, a problem that is not unique to New… Read More
  • Business and Markets

    The Antibiotic Gap: It’s All of the Above

    Here’s a business-section column at the New York Times on the problem of antibiotic drug discovery. To those of us following the industry, the problems of antibiotic drug discovery are big pieces of furniture that we’ve lived with all our lives; we hardly even notice if we bump into them again. You’d think that readers… Read More
  • Drug Development

    K. C. Nicolaou on Drug Discovery

    K. C. Nicolaou has an article in the latest Angewandte Chemie on the future of drug discovery, which may seem a bit surprising, considering that he’s usually thought of as Mister Total Synthesis, rather than Mister Drug Development Project. But I can report that it’s relentlessly sensible. Maybe too sensible. It’s such a dose of… Read More
  • Drug Development

    How to Run a Drug Project: Are There Any Rules at All?

    Here’s an article from David Shayvitz at Forbes whose title says it all: “Should a Drug Discovery Team Ever Throw in the Towel?” The easy answer to that is “Sure”. The hard part, naturally, is figuring out when. You don’t have to be an expensive management consultant to realize that it would be helpful for… Read More
  • Business and Markets

    Two Looks At Drug Industry Productivity

    Matthew Herper has a really interesting story in Forbes on a new report that attempts to rank biopharma companies by their R&D abilities. Richard Evans of Sector and Sovereign Health (ex-Roche) has ranked companies not on their number of drugs, but on their early-stage innovation. He counts patents, for example, but not the later ones… Read More
  • Academia (vs. Industry)

    Where the Talent Comes From

    I occasionally talk about the ecosystem of the drug industry being harmed by all the disruptions of recent years, and this post by Bruce Booth is exactly the sort of thing that fits that category. He’s talking about how much time it takes to get experience in this field, and what’s been happening to the… Read More
  • Clinical Trials

    AstraZeneca Looks At Its Own History, And Cringes

    While we’re talking about AstraZeneca, here’s a look at their recent drug development history from the inside. The company had undertaken a complete review of its portfolio and success rates (as well they might, given how things have been going overall). In this article, we discuss the results of a comprehensive longitudinal review of A… Read More
  • Drug Development

    The Daily Show on Finding New Antibiotics

    A reader sent along news of this interview on “The Daily Show” with Martin Blaser of NYU. He has a book out, Missing Microbes, on the overuse of antibiotics and the effects on various microbiomes. And I think he’s got a lot of good points – we should only be exerting selection pressure where we… Read More
  • Drug Industry History

    One and Done

    Matthew Herper has a good piece in Forbes on Robert Duggan and Pharmacyclics. In the course of it, we learn this interesting (and perhaps disturbing) bit of information: Second acts in the biotech business are hard: 56% of the drug firms that received an FDA approval between 1950 and 2011 did so only once. And… Read More
...91011...